文献速递哮喘

重度哮喘结局指标的识别与评价:一项系统综述

Identifying and appraising outcome measures for severe asthma: a systematic review.
PubMed 文献 · Eur Respir J · 2023-04-03

该研究通过文献检索和改良Delphi法识别重度哮喘的候选、关键和优先结局指标,并采用COSMIN标准评价其测量学性能。共识别96个候选、55个关键和24个优先结局指标,但仅2个指标(重度哮喘问卷和儿童哮喘控制测试)有重度哮喘患者参与开发,且多数优先指标证据确定性低至极低。

要点

  • 重度哮喘优先结局指标中仅2个有重度哮喘患者参与开发。
  • 多数优先结局指标的测量学证据确定性为低至极低。
  • 无优先结局指标满足所有质量评价标准。

核心结论

  • 仅两个结局指标(重度哮喘问卷和儿童哮喘控制测试)具有可靠的重度哮喘开发数据。
  • 本综述为重度哮喘核心结局指标集的制定提供了依据。

研究设计与样本

  • 通过文献检索识别2018至2020年发表的候选结局指标。
  • 采用改良Delphi法在多利益相关方群体中筛选关键结局指标。
  • 使用改良COSMIN质量标准评价关键指标的初步验证研究。
  • 检索四个文献数据库(从建库至2020年7月20日)以识别优先结局指标的开发与验证研究。
  • 由两名评价员筛选文献、提取数据、评估方法学质量并按COSMIN分级证据。

主要发现

  • 共识别96个候选结局指标、55个关键结局指标和24个优先结局指标,涵盖临床、医疗利用、生活质量、哮喘控制和复合指标。
  • 32项研究报告了来自后三个领域的17个优先结局指标的测量学性能。
  • 仅重度哮喘问卷和儿童哮喘控制测试有重度哮喘患者参与开发。
  • 大多数优先结局指标在所有测量学属性上的证据确定性为低至极低。
  • 无优先结局指标满足所有质量评价标准。

关键数值与推荐

  • 共识别96个候选结局指标、55个关键结局指标和24个优先结局指标。
  • 32项研究报告了17个优先结局指标的测量学性能。
  • 仅重度哮喘问卷和儿童哮喘控制测试有重度哮喘患者参与开发。
  • 大多数优先结局指标的证据确定性为低至极低,且无指标满足所有质量标准。

临床怎么用

  • 选择重度哮喘结局指标时应优先考虑有重度哮喘患者参与开发的工具。
  • 使用现有优先结局指标时需注意其测量学证据确定性多为低至极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Valid outcome measures are imperative to evaluate treatment response, yet the suitability of existing end-points for severe asthma is unclear. This review aimed to identify outcome measures for severe asthma and appraise the quality of their measurement properties. METHODS: A literature search was performed to identify "candidate" outcome measures published between 2018 and 2020. A modified Delphi exercise was conducted to select "key" outcome measures within healthcare professional, patient, pharmaceutical and regulatory stakeholder groups. Initial validation studies for "key" measures were rated against modified quality criteria from COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN). The evidence was discussed at multi-stakeholder meetings to ratify "priority" outcome measures. Subsequently, four bibliographic databases were searched from inception to 20 July 2020 to identify development and validation studies for these end-points. Two reviewers screened records, extracted data, assessed their methodological quality and graded the evidence according to COSMIN. RESULTS: 96 outcome measures were identified as "candidates", 55 as "key" and 24 as "priority" for severe asthma, including clinical, healthcare utilisation, quality of life, asthma control and composite. 32 studies reported measurement properties of 17 "priority" end-points from the latter three domains. Only the Severe Asthma Questionnaire and Childhood Asthma Control Test were developed with input from severe asthma patients. The certainty of evidence was "low" to "very low" for most "priority" end-points across all measurement properties and none fulfilled all quality standards. CONCLUSIONS: Only two outcome measures had robust developmental data for severe asthma. This review informed development of core outcome measures sets for severe asthma.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Rattu A, Khaleva E, Brightling C, et al. Identifying and appraising outcome measures for severe asthma: a systematic review. Eur Respir J. 2023. PMID: 36549712. doi:10.1183/13993003.01231-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。